1.0 Objectives 
1.1 To evaluate the safety and efficacy of a series of 
sequential treatments for patients with CML, where each 
treatment is designed to induce a population of Ph- 
cells (see schema) : 
1.11 Initial therapy with interferon alpha in patients 
with 1st chronic phase disease 
12 Treatment with cytoreductive chemotherapy (high 
dose cytarabine, daunorubicin, followed by G-CSF) 
and collection of Ph- enriched peripheral blood 
stem cells (PBSC) during the marrow recovery phase 
1.13 After marrow harvest treatment with high dose 
cyclophosphamide/TBI and autologous PBSC/marrow 
transplantation 
1.14 Post-transplant maintenance treatment with 
interferon alpha 
1.2 To investigate in vitro the feasibility, safety and 
efficacy of possible genetic therapy approaches to the 
treatment of CML using retroviral vectors, in hopes of 
applying these approaches in future autologous 
transplantation protocols. 
Recombinant DNA Research, Volume 16 
[143] 
